SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)  May 9, 2008

Inverness Medical Innovations, Inc.

Delaware (State or other jurisdiction of incorporation)		001-16789 (Commission file number)		04-3565120 (IRS Employer Identification No.)

51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453
(Address of principal executive offices)

Registrant’s telephone number, including area code: (781) 647-3900

Not Applicable
(Former name or former address, if changed since last report)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

ITEM 8.01     OTHER EVENTS

     On May 9, 2008, the conversion price under the Company’s $150 million of outstanding 3% convertible senior subordinated notes due 2016 (the “Notes”) was adjusted $52.30 to $43.98. At the adjusted conversion price, the Notes are convertible into an aggregate 3,410,641 shares of common stock. Under the terms of the indenture governing the Notes, the conversion price was subject to adjustment on May 9, 2008 if the 30 day volume-weighted average trading price of Inverness common stock as of such date was lower than $40.23.

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 15, 2008